Fairmount Funds Management LLC Viridian Therapeutics, Inc.\De Transaction History
Fairmount Funds Management LLC
- $498 Million
- Q4 2024
A detailed history of Fairmount Funds Management LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,445,813 shares of VRDN stock, worth $56.1 Million. This represents 13.28% of its overall portfolio holdings.
Number of Shares
3,445,813
Previous 3,445,813
-0.0%
Holding current value
$56.1 Million
Previous $78.4 Million
15.74%
% of portfolio
13.28%
Previous 12.74%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$77.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$74.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$73.6 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$63.2 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$57.3 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $649M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...